高危前列腺癌SBRT联合盆腔淋巴结照射后2至5年累积毒性
该单中心回顾性研究纳入101例高危前列腺癌患者,接受前列腺36.25 Gy/5次SBRT并同步盆腔淋巴结25 Gy及6-18个月ADT。中位随访43.8个月,晚期1-2级GI毒性4%、GU毒性13%,无≥3级毒性;5年生化复发无生存率89.5%。
要点
- 晚期1-2级GI毒性发生率4%,GU毒性发生率13%,无≥3级GI或GU毒性。
- 5年生化复发无生存率89.5%,远处转移无生存率96.2%,总生存率98.8%。
- SBRT 5次联合盆腔淋巴结照射在高危前列腺癌中可行且晚期毒性低。
核心结论
- 5次SBRT联合盆腔淋巴结照射在高危前列腺癌患者中可行,晚期GU和GI毒性发生率低。
研究设计与样本
- 回顾性分析101例高危前列腺癌患者,2019年8月至2023年5月接受SBRT。
- 治疗方案为前列腺36.25 Gy/5次,同步盆腔淋巴结25 Gy,并接受6至18个月ADT。
- 毒性按CTCAE 4.0版前瞻性评估,晚期毒性定义为SBRT后≥3个月发生的事件。
- 生存结局采用Kaplan-Meier法估计。
主要发现
- 中位随访43.8个月(范围26-70个月),所有患者至少随访24个月。
- 晚期1-2级GI毒性4例(4%),包括3例直肠出血和1例大便失禁。
- 晚期1-2级GU毒性13例(13%),其中5例为2级(5%)。
- 未观察到≥3级GI或GU毒性。
- 5年生化复发无生存率89.5%,远处转移无生存率96.2%,总生存率98.8%。
临床怎么用
- 对于高危前列腺癌患者,可考虑5次SBRT联合盆腔淋巴结照射,但需关注晚期GU和GI毒性。
- 治疗期间及治疗后应按照CTCAE 4.0版前瞻性评估并记录泌尿生殖和胃肠道毒性。
局限性
- 原文为单中心回顾性研究,样本量101例,随访时间有限。
- 原文指出正在进行的随机试验将提供关于SBRT联合盆腔淋巴结照射作用的确定性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Stereotactic body radiotherapy (SBRT) is increasingly used for localized prostate cancer, but data on SBRT with pelvic nodal irradiation in patients with high-risk disease remain limited. We report late genitourinary (GU) and gastrointestinal (GI) toxicities and clinical outcomes in patients with high-risk prostate cancer treated with SBRT in 5 fractions to the prostate and pelvic lymph nodes. MATERIALS AND METHODS: We reviewed 101 patients with high-risk prostate cancer treated with SBRT between August 2019 and May 2023. Treatment consisted of 36.25 Gy in 5 fractions to the prostate with a simultaneous dose of 25 Gy to the pelvic lymph nodes. Patients received 6 to 18 months of androgen deprivation therapy. Toxicity was prospectively assessed according to CTCAE version 4.0. Late toxicity was defined as events occurring ≥ 3 months after SBRT. Survival outcomes were estimated using Kaplan-Meier methods. RESULTS: All patients had a minimum follow-up of 24 months. With a median follow-up of 43.8 months (range 26-70 months), late grade 1 and 2 GI toxicity occurred in 4 patients (4%), including three cases of rectal bleeding and one case of fecal incontinence. Late grade 1 and 2 GU toxicity occurred in 13 patients (13%), including 5 grade 2 events (5%). No grade ≥ 3 GI or GU toxicity was observed. The 5-year actuarial biochemical recurrence-free survival was 89.5%, with distant metastasis-free survival of 96.2% and overall survival of 98.8%. CONCLUSION: SBRT delivered in five fractions with pelvic nodal irradiation appears feasible and associated with low rates of late GU and GI toxicity in patients with high-risk prostate cancer. Ongoing randomized trials will provide definitive evidence regarding the role of SBRT with pelvic nodal irradiation in this population.
引用
- Martinez C, Cury F, Duclos M, et al. "Cumulative incidence of toxicity between 2 and 5 years following SBRT to the prostate and pelvis nodes in patients with high-risk prostate cancer ". Pract Radiat Oncol. 2026. PMID: 42435987. doi:10.1016/j.prro.2026.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。